0NDV Stock Overview
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
MorphoSys AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €67.70 |
| 52 Week High | €68.35 |
| 52 Week Low | €14.56 |
| Beta | 0.60 |
| 1 Month Change | 0.75% |
| 3 Month Change | 93.86% |
| 1 Year Change | 260.44% |
| 3 Year Change | -11.02% |
| 5 Year Change | -23.24% |
| Change since IPO | 366.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0NDV | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.3% | -1.9% | -0.9% |
| 1Y | 260.4% | -30.5% | -1.8% |
Return vs Industry: 0NDV exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0NDV exceeded the UK Market which returned -1.8% over the past year.
Price Volatility
| 0NDV volatility | |
|---|---|
| 0NDV Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0NDV's share price has been volatile over the past 3 months.
Volatility Over Time: 0NDV's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 524 | Jean-Paul Kress | www.morphosys.com |
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.
MorphoSys AG Fundamentals Summary
| 0NDV fundamental statistics | |
|---|---|
| Market cap | €2.55b |
| Earnings (TTM) | -€189.73m |
| Revenue (TTM) | €238.28m |
10.7x
P/S Ratio-13.4x
P/E RatioIs 0NDV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NDV income statement (TTM) | |
|---|---|
| Revenue | €238.28m |
| Cost of Revenue | €58.35m |
| Gross Profit | €179.92m |
| Other Expenses | €369.66m |
| Earnings | -€189.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | -5.04 |
| Gross Margin | 75.51% |
| Net Profit Margin | -79.63% |
| Debt/Equity Ratio | 3,428.8% |
How did 0NDV perform over the long term?
See historical performance and comparison